ICD-10-CM Code D46

Myelodysplastic syndromes

Version 2021 Non-Billable Code

Not Valid for Submission

D46 is a "header" nonspecific and non-billable code code, consider using a code with a higher level of specificity for a diagnosis of myelodysplastic syndromes. The code is NOT valid for the year 2021 for the submission of HIPAA-covered transactions.

Short Description:Myelodysplastic syndromes
Long Description:Myelodysplastic syndromes

Consider the following ICD-10 codes with a higher level of specificity:

  • D46.0 - Refractory anemia without ring sideroblasts, so stated
  • D46.1 - Refractory anemia with ring sideroblasts
  • D46.2 - Refractory anemia with excess of blasts [RAEB]
  • D46.20 - Refractory anemia with excess of blasts, unspecified
  • D46.21 - Refractory anemia with excess of blasts 1
  • D46.22 - Refractory anemia with excess of blasts 2
  • D46.4 - Refractory anemia, unspecified
  • D46.9 - Myelodysplastic syndrome, unspecified
  • D46.A - Refractory cytopenia with multilineage dysplasia
  • D46.B - Refractory cytopenia with multilineage dysplasia and ring sideroblasts
  • D46.C - Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
  • D46.Z - Other myelodysplastic syndromes

Tabular List of Diseases and Injuries

The Tabular List of Diseases and Injuries is a list of ICD-10 codes, organized "head to toe" into chapters and sections with guidance for inclusions, exclusions, descriptions and more. The following references are applicable to the code D46:

Use Additional Code

Use Additional Code
The “use additional code” indicates that a secondary code could be used to further specify the patient’s condition. This note is not mandatory and is only used if enough information is available to assign an additional code.
  • code for adverse effect, if applicable, to identify drug T36 T50

Type 2 Excludes

Type 2 Excludes
A type 2 excludes note represents "Not included here". An excludes2 note indicates that the condition excluded is not part of the condition represented by the code, but a patient may have both conditions at the same time. When an Excludes2 note appears under a code, it is acceptable to use both the code and the excluded code together, when appropriate.
  • drug-induced aplastic anemia D61.1

Clinical Information

  • MYELODYSPLASTIC SYNDROMES-. clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. they predominantly affect patients over 60 are considered preleukemic conditions and have high probability of transformation into acute myeloid leukemia.

Code Classification

  • Neoplasms (C00–D48)
    • Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes (D37-D48)
      • Myelodysplastic syndromes (D46)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021

Information for Patients

Myelodysplastic Syndromes

Also called: MDS

Your bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. It contains immature cells, called stem cells. The stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting. If you have a myelodysplastic syndrome, the stem cells do not mature into healthy blood cells. Many of them die in the bone marrow. This means that you do not have enough healthy cells, which can lead to infection, anemia, or easy bleeding.

Myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. If you have symptoms, they may include

  • Shortness of breath
  • Weakness or feeling tired
  • Skin that is paler than usual
  • Easy bruising or bleeding
  • Pinpoint spots under the skin caused by bleeding
  • Fever or frequent infections

Myelodysplastic syndromes are rare. People at higher risk are over 60, have had chemotherapy or radiation therapy, or have been exposed to certain chemicals. Treatment options include transfusions, drug therapy, chemotherapy, and blood or bone marrow stem cell transplants.

NIH: National Cancer Institute

  • Bone marrow transplant (Medical Encyclopedia)
  • Bone marrow transplant - discharge (Medical Encyclopedia)

[Learn More]